What podcasts are saying about GLP-1 drugs.
custom feeds from $8.99/mo
Two shows, one fight: are these drugs costing people their muscle?
“there is an inordinate amount of muscle loss that goes along with the weight loss.”
“We're frequently treating lean mass and skeletal muscle mass as though they're interchangeable. They're not.”
“I think we need to stop making the leap from lean mass loss to muscle damage every time a new study comes out.”
Read the story
A quieter stretch, and two shows arguing about the same thing. Dr. Ken Berry, a family physician, repeated the warning on his own show: for patients who keep their old diet, there is “an inordinate amount of muscle loss that goes along with the weight loss.”
Two days later the host of Weight & Measure walked through a new study comparing tirzepatide and semaglutide and said the alarm rests on a mix-up between lean mass and muscle. The gap between the two drugs looked like 2.1 percentage points, and shrank to about 0.1 once total weight loss was accounted for.
Both say muscle is worth protecting. They split on whether the drug or the measurement is the problem.
podcasts searched for GLP-1 drugs, before every briefing.



































































